Galmed Pharmaceuticals Ltd. SEC filings EOCN
Galmed Pharmaceuticals Ltd. has 381 filings in SEC EDGAR's recent list, going back to Dec 31, 2013. Its latest annual report, Form 20-F, was filed on Mar 31, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Sep 9, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| POS AM | Filing | Sep 2, 2026 | — |
| 424B3 | Prospectus | Jun 22, 2026 | — |
| 424B3 | Prospectus | Jun 8, 2026 | — |
| POS AM | Filing | Mar 31, 2026 | — |
| S-8 | Employee stock plan registration | Sep 19, 2025 | — |
| POS AM | Filing | Aug 28, 2025 | — |
| POS AM | Filing | Aug 28, 2025 | — |
| 424B3 | Prospectus | Aug 21, 2025 | — |
| F-1 | Registration statement (foreign issuer) | Aug 18, 2025 | — |
| POS AM | Filing | Apr 2, 2025 | — |
| S-8 | Employee stock plan registration | Jan 7, 2025 | — |
| F-3 | Shelf registration (foreign issuer) | Nov 14, 2024 | — |
| 424B3 | Prospectus | Oct 28, 2024 | — |
| F-1 | Registration statement (foreign issuer) | Oct 21, 2024 | — |
| 424B3 | Prospectus | Sep 9, 2024 | — |
| F-1 | Registration statement (foreign issuer) | Aug 30, 2024 | — |
| POS AM | Filing | Nov 22, 2023 | — |
| POS AM | Filing | Nov 1, 2023 | — |
| 424B4 | Prospectus | Jul 18, 2023 | — |
| F-1/A | Filing | Jul 13, 2023 | — |
| F-1/A | Filing | Jul 12, 2023 | — |
| FWP | Free writing prospectus | Jun 28, 2023 | — |
| F-1/A | Filing | Jun 28, 2023 | — |
| F-1 | Registration statement (foreign issuer) | Jun 16, 2023 | — |
| 424B5 | Prospectus supplement | Jul 1, 2022 | — |
| F-3 | Shelf registration (foreign issuer) | Mar 26, 2021 | — |
| 424B5 | Prospectus supplement | Feb 18, 2021 | — |
| 424B5 | Prospectus supplement | Feb 16, 2021 | — |
| 424B5 | Prospectus supplement | May 15, 2020 | — |
| S-8 POS | Filing | Oct 29, 2018 | — |
| S-8 | Employee stock plan registration | Sep 20, 2018 | — |
| 424B5 | Prospectus supplement | Jun 21, 2018 | — |
| FWP | Free writing prospectus | Jun 18, 2018 | — |
| 424B5 | Prospectus supplement | Jun 18, 2018 | — |
| 424B5 | Prospectus supplement | Apr 4, 2018 | — |
| F-3 | Shelf registration (foreign issuer) | Mar 26, 2018 | — |
| 424B5 | Prospectus supplement | Dec 22, 2017 | — |
| 424B5 | Prospectus supplement | Aug 7, 2017 | — |
| 424B5 | Prospectus supplement | Jun 1, 2016 | — |
| S-8 | Employee stock plan registration | Aug 11, 2015 | — |
| F-3 | Shelf registration (foreign issuer) | Mar 31, 2015 | — |
| 424B4 | Prospectus | Mar 13, 2014 | — |
| F-1MEF | Filing | Mar 12, 2014 | — |
| F-1/A | Form f-1/a | Mar 11, 2014 | — |
| F-1/A | Form f-1/a | Feb 28, 2014 | — |
| F-1 | Registration statement (foreign issuer) | Feb 6, 2014 | — |
Showing 46 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- EOCN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Israel
- Headquarters
- Ramat Gan, Israel
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1595353
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.